Table 2 Tumour characteristics
S. no | Variable (N = 32) | Â |
|---|---|---|
1. | Size (cm) | No. of patients (percentage) |
|  | Range: 1.4–7.0 cm | |
|  | ≤ 2 | 05 (15.62%) |
|  | > 2 ≤ 5 | 20 (62.50%) |
| Â | > 5 | 07 (21.80%) |
2. | T stage (according to AJCC 8th edition) | No. of patients (percentage) |
| Â | T1 | 4 (12.50%) |
| Â | T2 | 17 (53.12%) |
| Â | T3 | 3 (9.30 %) |
| Â | T4a | 0 (0%) |
| Â | T4b | 7 (21.80%) |
| Â | T4c | 0 (0%) |
| Â | T4d | 1 (3.12%) |
3. | N stage (according to AJCC 8th edition) | No. of patients (percentage) |
| Â | N0 | 14 (43.75%) |
| Â | N1 | 14 (43.75%) |
| Â | N2a | 2 (6.25%) |
| Â | N2b | 1 (3.12%) |
| Â | N3a | 0 (0%) |
| Â | N3b | 1 (3.12%) |
| Â | N3c | 0 (0%) |
4 | Stage-wise distribution | No. of patients (percentage) |
| Â | IA | 3 (9.30%) |
| Â | IB | 0 (0%) |
| Â | IIA | 12 (37.50%) |
| Â | IIB | 5 (15.62%) |
| Â | IIIA | 4 (12.50%) |
| Â | IIIB | 7 (21.80%) |
| Â | IIIC | 1 (3.12%) |
| Â | IV | 0 (0%) |
5 | Molecular characteristics | |
i | Oestrogen receptor | No. of patients (percentage) |
| Â | Positive | 16 (50%) |
| Â | Negative | 16 (50%) |
ii | Progesterone receptor | No. of patients (percentage) |
| Â | Positive | 14 (43.75%) |
| Â | Negative | 18 (56.25%) |
iii | HER2/neu receptor | No. of patients (percentage) |
| Â | Positive | 10 (31.25%) |
| Â | Negative | 22 (68.75%) |